Literature DB >> 15703562

Cholestatic syndromes.

Michael Trauner1, James L Boyer.   

Abstract

Further insights into the cellular and molecular mechanisms underlying hepatobiliary transport function and its regulation now permit a better understanding of the pathogenesis and treatment options of cholestatic liver diseases. Identification of the molecular basis of hereditary cholestatic syndromes will result in an improved diagnosis and management of these conditions. New insights into the pathogenesis of extrahepatic manifestations of cholestasis (eg, pruritus) have facilitated new treatment strategies. Important new studies have been published about the pathogenesis, clinical features, diagnosis, and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, total parenteral nutrition-induced cholestasis, drug-induced cholestasis, and viral cholestatic syndromes.

Entities:  

Year:  2003        PMID: 15703562     DOI: 10.1097/00001574-200305000-00005

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  3 in total

Review 1.  [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?].

Authors:  J Pausch; M Gatzen
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

2.  Specific microbiome changes in a mouse model of parenteral nutrition associated liver injury and intestinal inflammation.

Authors:  J Kirk Harris; Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Sophie A Fillon; Charles E Robertson; Brandie D Wagner; Mark J Stevens; Norman R Pace; Ronald J Sokol
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

3.  A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid.

Authors:  Chunlei Li; Kunyu Zheng; Yiran Chen; Chengmei He; Suying Liu; Yunjiao Yang; Mengtao Li; Xiaofeng Zeng; Li Wang; Fengchun Zhang
Journal:  Ther Adv Chronic Dis       Date:  2022-07-26       Impact factor: 4.970

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.